A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Calliditas Therapeutics Ab stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 65 shares of CALT stock, worth $2,523. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65
Holding current value
$2,523
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$20.04 - $25.66 $1,302 - $1,667
65 New
65 $1,000
Q2 2021

Aug 16, 2021

SELL
$26.02 - $31.17 $358,607 - $429,584
-13,782 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$27.01 - $32.92 $372,251 - $453,703
13,782 New
13,782 $380,000
Q4 2020

Feb 16, 2021

SELL
$23.34 - $36.65 $570,009 - $895,066
-24,422 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$21.61 - $25.69 $231,875 - $275,653
-10,730 Reduced 30.52%
24,422 $586,000
Q2 2020

Aug 14, 2020

BUY
$19.17 - $23.2 $673,863 - $815,526
35,152 New
35,152 $816,000

Others Institutions Holding CALT

About Calliditas Therapeutics AB


  • Ticker CALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,624,800
  • Market Cap $1.03B
  • Description
  • Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...
More about CALT
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.